VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

AACR 2022 | ENDOLA: olaparib, metronomic cyclophosphamide and metformin in advanced endometrial cancer

Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses the rationale behind and results of the ENDOLA trial (NCT02755844), a Phase I/II study evaluating a chemotherapy-free combination of olaparib, metronomic cyclophosphamide, and metformin in recurrent advanced or metastatic endometrial cancer (EC) patients. First-line treatment for EC is platinum-based chemotherapy but there are currently no defined, effective late-line therapies. The primary endpoint of non-progression at 10 weeks was reached with a rate of 61.5%. Median progression-free survival was 5.1 months. Metronomic cyclophosphamide regimen may enhance the effects of olaparib because it is an anti-angiogenic alkylating agent, and metformin may increase the anti-proliferative effects of olaparib because it downregulates IGF1R and PI3K-AKT-mTor pathways, which are commonly altered in EC. There was only one dose limiting toxicity (DLT) at a regimen of 300mg olaparib with 50mg metronomic cyclophosphamide and 50mg metformin per day. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter